1
|
Xu W, Zou X, Zha Y, Zhang J, Bian H, Shen Z. Novel Bis-Artemisinin-Phloroglucinol hybrid molecules with dual anticancer and immunomodulatory Activities: Synthesis and evaluation. Bioorg Chem 2023; 139:106705. [PMID: 37406517 DOI: 10.1016/j.bioorg.2023.106705] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 06/15/2023] [Accepted: 06/26/2023] [Indexed: 07/07/2023]
Abstract
Bis-(10-deoxydihydroartemisinin)-phloroglucinol (9), has been synthesized in a one-step reaction and has demonstrated strong inhibition to cancer cell proliferation and immunosuppressive activity. The structure modification of the compound reduced its cytotoxicity, and among the analogs, bis-(10-deoxydihydroartemisinin)-phloroglucinol phenyl decanoate (16) showed significant reduction of ear swelling in a mouse model for DNFB-induced delayed-type hypersensitivity without observable toxicity in a dose-dependent manner.
Collapse
Affiliation(s)
- Wei Xu
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai 200025, China
| | - Xiaosu Zou
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cai Lun Road, Shanghai 201203, China
| | - Yufeng Zha
- Yunnan Baiyao Group Co. Ltd., 3686 Yunnan Baiyao Street, Kunming 650200, China
| | - Jinghua Zhang
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai 200025, China
| | - Hongzhu Bian
- Yunnan Baiyao Group Co. Ltd., 3686 Yunnan Baiyao Street, Kunming 650200, China
| | - Zhengwu Shen
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai 200025, China; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cai Lun Road, Shanghai 201203, China.
| |
Collapse
|
2
|
Yu J, Sheng S, Zou X, Shen Z. Dihydroartemisinin-ursodeoxycholic acid conjugate is a potential treatment agent for inflammatory bowel disease. Int Immunopharmacol 2023; 117:109918. [PMID: 36842236 DOI: 10.1016/j.intimp.2023.109918] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/13/2023] [Accepted: 02/16/2023] [Indexed: 02/28/2023]
Abstract
BACKGROUND A novel artemisinin derivative, dihydroartemisinin-ursodeoxycholic acid conjugate (4), was found to exhibit strong immunosuppressive activity. Various methods were used to evaluate the immunosuppressive activity and mechanism of action of the compound to explore its potential applications. METHODS T cell proliferation, mixed lymphocyte reaction (MLR), and Th1/Th17 differentiation assays were used to evaluate the immunosuppressive activity of the compound. Differentially expressed genes from RNA sequencing were analysed with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, while enriched signalling pathways were further validated by western blotting (WB). In vivo efficacy was validated with delayed-type hypersensitivity (DTH) mouse models and dextran sodium sulphate (DSS)-induced inflammatory bowel disease (IBD) mouse model. RESULTS Compound 4 inhibited concanavalin A -induced mouse splenic T cell proliferation (IC50 = 15 nM) and anti-CD3/CD28-induced human primary T cell proliferation (IC50 = 30 nM) while also reducing the secretion of hIFN-γ. Compound 4 exhibited similar inhibitory activity in MLR assay. Compound 4 dose-dependently inhibited human Th1/Th17 differentiation. The KEGG pathway enrichment analysis indicated that the genes related to T cell activation signalling pathways PI3K-AKT, MAPK, and NF-κB were significantly enriched. WB confirmed that compound 4 inhibited the AKT/MAPK and NF-κB signalling pathways. Compound 4 dose-dependently inhibited ear and foot pad swelling in DTH mouse models. In the DSS-induced IBD mouse model, compound 4 significantly decreased the disease activity index and colon density, and inhibited splenomegaly of the mice. CONCLUSION The in vitro and in vivo results indicated that compound 4 has the potential to be developed into an anti-IBD drug.
Collapse
Affiliation(s)
- Jingfeng Yu
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
| | - Sihan Sheng
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
| | - Xiaosu Zou
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
| | - Zhengwu Shen
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai 200025, China; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China.
| |
Collapse
|
3
|
Zou X, Liu C, Li C, Fu R, Xu W, Bian H, Dong X, Zhao X, Xu Z, Zhang J, Shen Z. Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents. Eur J Med Chem 2021; 225:113754. [PMID: 34399390 DOI: 10.1016/j.ejmech.2021.113754] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 08/05/2021] [Accepted: 08/05/2021] [Indexed: 11/20/2022]
Abstract
A series of dihydroartemisinin derivatives was synthesized, and their anti-proliferation activity against cancer cells was evaluated. Structure-activity relationship studies led to the discovery of dihydroartemisinin-bile acid conjugates that exhibit broad-spectrum anti-proliferation activities. Among them, the dihydroartemisinin-ursodeoxycholic acid conjugate (49) was the most potent, with IC50 values between 0.04 and 0.96 μM when tested to determine its inhibitory properties against 15 various cancer cell lines. In vivo experiments showed that compound 49 effectively suppressed tumor growth in an A549 cell xenograft model at the dosage of 10 mg/kg body weight and in Lewis lung cancer cell transplant model at the dosage of 12 mg/kg body weight.
Collapse
Affiliation(s)
- Xiaosu Zou
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 CaiLun Road, Shanghai, 201203, China
| | - Chang Liu
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, 200032, China
| | - Congcong Li
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 CaiLun Road, Shanghai, 201203, China
| | - Rong Fu
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai, 200025, China
| | - Wei Xu
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 CaiLun Road, Shanghai, 201203, China
| | - Hongzhu Bian
- Yunnan Baiyao Group Co. Ltd, 3686 Yunnan Baiyao Street, Kunming, 650200, China
| | - Xun Dong
- Yunnan Baiyao Group Co. Ltd, 3686 Yunnan Baiyao Street, Kunming, 650200, China
| | - Xiaozhen Zhao
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, 200032, China
| | - Zhenye Xu
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, 200032, China.
| | - Jinghua Zhang
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai, 200025, China.
| | - Zhengwu Shen
- School of Medicine, Shanghai Jiao Tong University, 280 South Chongqing Road, Shanghai, 200025, China; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 CaiLun Road, Shanghai, 201203, China.
| |
Collapse
|